Dasatinib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hormone-refractory Prostate Cancer

Conditions

Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer

Trial Timeline

Jul 1, 2007 → Feb 1, 2012

NCT ID

NCT00570700

About Dasatinib

Dasatinib is a phase 2 stage product being developed by Bristol Myers Squibb for Hormone-refractory Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00570700. Target conditions include Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer.

What happened to similar drugs?

0 of 2 similar drugs in Hormone-refractory Prostate Cancer were approved

Approved (0) Terminated (0) Active (2)

🔄amg 162AmgenPhase 3

🔄DenosumabAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00454753	Pre-clinical	Completed	—	—	—
NCT04115059	Phase 1	Terminated	Nov 4, 2019	Dec 31, 2021	Waldenstrom Macroglobulinemia
NCT02297139	Phase 2	Completed	Jul 31, 2015	May 15, 2022	Multiple Indications Cancer
NCT02546791	Pre-clinical	Completed	Jul 22, 2015	Mar 29, 2017	Leukemia
NCT02428855	Phase 2	Completed	Apr 1, 2015	Feb 1, 2018	Cholangiocarcinoma
NCT01850004	Phase 2	Completed	Jan 22, 2014	Oct 8, 2021	Chronic Phase Chronic Myeloid Leukemia
NCT01471106	Phase 2	Completed	Jan 21, 2014	May 30, 2024	Breast Cancer
NCT02389972	Pre-clinical	Completed	Apr 11, 2013	Jul 13, 2017	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NCT01802450	Phase 2	UNKNOWN	Mar 1, 2013	Dec 1, 2016	Chronic Myeloid Leukemia
NCT01660906	Approved	Completed	Dec 1, 2012	Oct 1, 2015	Chronic Phase Chronic Myeloid Leukemia
NCT01514864	Phase 2	Terminated	May 31, 2012	Jul 23, 2014	Carcinoma, Non-small Cell Lung
NCT01460160	Phase 2	Completed	Apr 13, 2012	Jun 1, 2021	Leukemia, Pediatric
NCT01092728	Phase 2	Terminated	Mar 1, 2011	Aug 1, 2014	Melanoma
NCT00918463	Phase 2	Terminated	Jun 1, 2009	May 23, 2011	Diffuse Large B-cell Lymphoma
NCT00777036	Phase 2	Completed	Mar 20, 2009	Jan 27, 2025	Leukemia
NCT00858403	Phase 2	Terminated	Mar 1, 2009	Jul 1, 2010	Lung Cancer
NCT00764309	Phase 1/2	Completed	Jan 1, 2009	Apr 1, 2011	Scleroderma
NCT00787267	Phase 2	Terminated	Sep 1, 2008	Jun 1, 2013	Non Small Cell Lung Cancer
NCT00706641	Pre-clinical	Completed	Jun 1, 2008	Dec 1, 2012	Transitional Cell Carcinoma of the Bladder
NCT00652574	Phase 1	Completed	Mar 12, 2008	Oct 7, 2022	Malignant Pleural Mesothelioma

Competing Products

8 competing products in Hormone-refractory Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
Enzalutamide	Astellas Pharma	Phase 2	35
YM598	Astellas Pharma	Phase 2	27
Zoledronic acid + Estramustine + Docetaxel	Novartis	Phase 2	35
amg 162	Amgen	Phase 3	40
Denosumab	Amgen	Phase 3	40
IV Bisphosphonate q 4 weeks	Amgen	Phase 2	35
ILX651	Sanofi	Phase 2	35
VIR-5500	Vir Biotechnology	Phase 1	30